Department of Head and Neck Surgery-Otorhinolaryngology, Ogaki Municipal Hospital, Ogaki, Gifu-ken, Japan.
Jpn J Clin Oncol. 2011 Mar;41(3):348-52. doi: 10.1093/jjco/hyq196. Epub 2010 Nov 24.
We investigated the efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck cancer, as an alternative to cisplatin and 5-fluorouracil.
A total of 31 patients were enrolled in this study. S-1 was administered orally twice a day for 14 days followed by a 2-week rest. Nedaplatin was intravenously administered on day 4. If possible, two courses of chemotherapy were performed. The radiotherapy was started concurrently with the administration of S-1.
The overall complete response rate was 81%. The 2-year overall survival rate was 96%. The 2-year relapse-free survival rate was 94%. The main adverse events were hematological toxicity, mucositis and dermatitis.
Our findings suggest that this therapeutic regimen has either an equal or lower toxicity than the conventional cisplatin and 5-fluorouracil, and that it has equal efficacy with regard to the clinical response and short-term outcome. Moreover, it is possible to successfully perform this treatment in an outpatient setting.
我们研究了奈达铂和 S-1 联合放化疗治疗头颈部癌症的疗效和毒性，作为顺铂和 5-氟尿嘧啶的替代方案。
本研究共纳入 31 例患者。S-1 口服，每日 2 次，连用 14 天，休息 2 周。奈达铂于第 4 天静脉给药。如有可能，进行两个疗程的化疗。S-1 给药的同时开始放疗。
总完全缓解率为 81%。2 年总生存率为 96%。2 年无复发生存率为 94%。主要不良反应为血液学毒性、黏膜炎和皮炎。
我们的研究结果表明，该治疗方案的毒性与传统的顺铂和 5-氟尿嘧啶相当或更低，在临床反应和短期结局方面具有同等疗效。此外，该治疗方案有可能在门诊环境中成功实施。
Zotero 插件